62 related articles for article (PubMed ID: 29572704)
1. Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
Shida D; Yoshida T; Tanabe T; Tsukamoto S; Ochiai H; Kanemitsu Y
Ann Surg Oncol; 2018 Jun; 25(6):1646-1653. PubMed ID: 29572704
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases.
Rietveld PCS; Guchelaar NAD; van Eerden RAG; de Boer NL; de Bruijn P; Sassen SDT; Madsen EVE; Koch BCP; Verhoef C; Burger JWA; Mathijssen RHJ; Koolen SLW
Biomed Pharmacother; 2024 Jul; 176():116820. PubMed ID: 38810398
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of stage IV patients with colorectal cancer treated in a single institution: What is the key to the long-term survival?
Mukai T; Uehara K; Aiba T; Nakamura H; Ebata T; Nagino M
J Anus Rectum Colon; 2018; 2(1):16-24. PubMed ID: 31583318
[TBL] [Abstract][Full Text] [Related]
4. The Validity of a New Edition of Classification for Ovarian Metastasis from Colorectal Cancer.
Yoshihara T; Noura S; Tanida T; Ogino T; Noguchi K; Nagase H; Hirota M; Tomimaru Y; Imamura H; Dono K
J Anus Rectum Colon; 2021; 5(1):40-45. PubMed ID: 33537499
[TBL] [Abstract][Full Text] [Related]
5. Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome.
Matsumoto A; Shimada Y; Nakano M; Ozeki H; Yamai D; Murata M; Ishizaki F; Nyuzuki H; Ikeuchi T; Wakai T
Clin J Gastroenterol; 2024 Jun; 17(3):451-456. PubMed ID: 38393537
[TBL] [Abstract][Full Text] [Related]
6. Hazard function analysis of prognosis after recurrent colorectal cancer.
Ise I; Kawai K; Nakano D; Takao M; Natsume S; Kato H; Nakamori S; Dejima A; Yamaguchi T
Langenbecks Arch Surg; 2024 Apr; 409(1):123. PubMed ID: 38613567
[TBL] [Abstract][Full Text] [Related]
7. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Geredeli C; Yasar N
World J Surg Oncol; 2018 Mar; 16(1):67. PubMed ID: 29587749
[TBL] [Abstract][Full Text] [Related]
9. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.
Ciliberto D; Staropoli N; Caglioti F; Chiellino S; Ierardi A; Ingargiola R; Botta C; Arbitrio M; Correale P; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2018 May; 125():69-77. PubMed ID: 29650279
[TBL] [Abstract][Full Text] [Related]
10. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
11. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
12. The start of a new wave: Developments in proteasome inhibition in multiple myeloma.
Yong K; Gonzalez-McQuire S; Szabo Z; Schoen P; Hajek R
Eur J Haematol; 2018 Mar; ():. PubMed ID: 29603798
[TBL] [Abstract][Full Text] [Related]
13. MRI Detection of Intratumoral Fat in Colorectal Liver Metastases After Preoperative Chemotherapy.
Nakai Y; Gonoi W; Hagiwara A; Nishioka Y; Abe H; Shindoh J; Hasegawa K
AJR Am J Roentgenol; 2018 May; 210(5):W196-W204. PubMed ID: 29629795
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
Machida M; Fukunaga S; Hara T
Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Kawahara H; Mouri T; Ishida K; Matsumoto N; Akiba T; Yanaga K
Anticancer Res; 2018 Apr; 38(4):2419-2422. PubMed ID: 29599371
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
[TBL] [Abstract][Full Text] [Related]
17. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Matsuda C; Honda M; Tanaka C; Kondo K; Takahashi T; Kosugi C; Tokunaga Y; Takemoto H; Kim HM; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1035-1041. PubMed ID: 29644459
[TBL] [Abstract][Full Text] [Related]
20. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach.
Schmoll HJ; Arnold D; de Gramont A; Ducreux M; Grothey A; O'Dwyer PJ; Van Cutsem E; Hermann F; Bosanac I; Bendahmane B; Mancao C; Tabernero J
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1197-1204. PubMed ID: 29644408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
